Oramed to Present at Three Upcoming Conferences

//Oramed to Present at Three Upcoming Conferences

Oramed to Present at Three Upcoming Conferences

NEW YORK, Sept. 3, 2019 /PRNewswire/ — Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that the company will present at three conferences in New York in the first half of September 2019.

Oramed Pharmaceuticals Logo (PRNewsfoto/Oramed Pharmaceuticals Inc)

RHK Capital 4th Annual Disruptive Growth Conference
Date:                September 4, 2019
Time:                2:00 p.m.
Location:          599 Lexington Avenue, New York, NY
Presenter:        Estee Yaari,  Director, Corporate Communications

H. C. Wainwright 21st Annual Global Investment Conference
Date:                September 9, 2019
Time:                9:10 a.m.
Location:          Lotte New York Palace Hotel, New York
Presenter:        Nadav Kidron, CEO 

The Future of Healthcare Panel Discussion
Date:                September 12, 2019
Time:                6:00 p.m.
Location:          SOSA NYC
Presenter:        Nadav Kidron, CEO

About Oramed

Oramed Pharmaceuticals is a platform technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, with offices in New York and Israel, Oramed has developed a novel Protein Oral Delivery (POD) technology that is based on more than 30 years of research by scientists at Jerusalem’sHadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary lead candidate, ORMD-0801, which has the potential to be the first commercial oral insulin capsule for the treatment of Type 2 and Type 1 diabetes. The Company has completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 (Glucagon-like peptide-1) analog capsule, ORMD-0901, which has potential to be the first orally-ingestible GLP-1 analog.

For more information, please visit www.oramed.com

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed’s reports filed from time to time with the U.S. Securities and Exchange Commission.

 

Company Contact:
Oramed PharmaceuticalsEstee YaariOffice: +972-2-566-0001 ext. 2
US: 1 844 9 ORAMED ext. 2
Email:  estee@oramed.com

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/oramed-to-present-at-three-upcoming-conferences-300910444.html

SOURCE Oramed Pharmaceuticals Inc.

2019-09-03T08:25:00+00:00 Categories: Press Releases|Tags: |